-
Security Type
-
Common Stock
-
Categories
-
Technology, Healthcare & Medical
-
Min Investment
-
$250
-
Location
-
NORTH CHICAGO, IL
-
Offering Date
-
July 01, 2021
-
Expected Close Date
-
April 27, 2022
-
Target Raise
-
$10.00K-$1.07M
-
No. Investors
-
490
-
Security Price
-
$1
-
Valuation
-
$9,990,000
- Number of Employees
- 8
- Cash
- $118,858
- Revenue
- $0
- Short Term Debt
- $212,017
- Cost of Goods
- $0
- Long Term Debt
- $0
- Net Income
- $-38,932
Company Description
Covira is an early-stage biotech company, a spinout from The University of Chicago, focusing on the prevention of post-surgical infections. Covira’s approach to solving post-operative infections can be transformative to the field and even Business Worldwide Magazine named Covira Surgical Among the 2021- Top 20 Most Innovative Companies to Watch. This microbiome-focused company is based on the work of Dr. John Alverdy, MD, a professor of surgery, practicing gastrointestinal surgeon and world authority on the prevention of post-surgical infections. Covira has developed a proprietary solution phosphate (Pi) conjugated polyethylene glycol (PEG) polymer to reduce infection risk and related complications following surgical procedures.
Perks
StartEngine OWNERS Exclusive Click here to learn more
$250+ Investment
StartEngine Owner’s Bonus
This offering is eligible for the StartEngine Owner’s 10% Bonus program. For details on this program, please see the Offering Summary section below.
$1,000+ Investment
Tier 1
Invest $1,000+ , you will receive 5% bonus shares.
$5,000+ Investment
Tier 2
Invest $5,000+ , you will receive 10% bonus shares.
$10,000+ Investment
Tier 3
Invest $10,000+ , you will receive 15% bonus shares.
$25,000+ Investment
Tier 4
Invest $25,000+ , you will receive 20% bonus shares.
$100,000+ Investment
Tier 5
Invest $100,000+ , you will receive 25% bonus shares.
Key Deal Facts
Market Opportunity: Covira estimates the US total available market for Pi-PEG's top three prioritized indications (Surgical Site Infections, Anastomotic Leak, Sepsis) to be $8.8B. The peak year net revenue forecast is projected to reach $2.5B by 2037 (Source: IQVIA).
Technology Platform: Pi-PEG is an orally administered anti-virulence agent to prevent postoperative infections and their progression to sepsis.
Management Team: Founder is a preeminent surgeon-scientist and world leader in GI surgical infection research, CEO is a proven life science executive from J&J, Abbott and four prior startups including two in the biotech space culminating in strategic sales to larger multinational corporations.